Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20074525
Rodgers JT, Haas W, Gygi SP, Puigserver P (2010) Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis. Cell Metab 11, 23-34 20074525
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (mouse)
Modsite: KDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease

S98-p - CLK2 (mouse)
Modsite: YDTDFRQsyEYHREN SwissProt Entrez-Gene
Orthologous residues
CLK2 (human): S98‑p, CLK2 iso2 (human): S98‑p, CLK2 iso3 (human): S98‑p, CLK2 (mouse): S98‑p, CLK2 (rat): S98‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  protein degradation

Y99-p - CLK2 (mouse)
Modsite: DTDFRQsyEYHRENS SwissProt Entrez-Gene
Orthologous residues
CLK2 (human): Y99‑p, CLK2 iso2 (human): Y99‑p, CLK2 iso3 (human): Y99‑p, CLK2 (mouse): Y99‑p, CLK2 (rat): Y99‑p
Characterization
Methods used to characterize site in vivo mutation of modification site
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  protein degradation

S342-p - CLK2 (mouse)
Modsite: EHHSTIVstRHYRAP SwissProt Entrez-Gene
Orthologous residues
CLK2 (human): S343‑p, CLK2 iso2 (human): , CLK2 iso3 (human): S342‑p, CLK2 (mouse): S342‑p, CLK2 (rat): S343‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
LY294002 insulin inhibit treatment-induced increase
Akt_inhibitor_VIII insulin inhibit treatment-induced increase
TG003 decrease

T343-p - CLK2 (mouse)
Modsite: HHSTIVstRHYRAPE SwissProt Entrez-Gene
Orthologous residues
CLK2 (human): T344‑p, CLK2 iso2 (human): , CLK2 iso3 (human): T343‑p, CLK2 (mouse): T343‑p, CLK2 (rat): T344‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), liver
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt2 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
LY294002 insulin inhibit treatment-induced increase
Akt_inhibitor_VIII insulin inhibit treatment-induced increase
TG003 decrease
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced

T24-p - FOXO1A (mouse)
Modsite: LPRQRSCtWPLPRPE SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease

S253-p - FOXO1A (mouse)
Modsite: sPRRRAAsMDNNSKF SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease

S21-p - GSK3A (mouse)
Modsite: sGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease

S9-p - GSK3B (mouse)
Modsite: SGRPRttsFAEsCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
refeeding increase
fasting decrease